Renal Protection with Rivaroxaban in Atrial Fibrillation: Insights from Real-World Evidence
by dr. Tjhia Theonardy Gilroy Yonathan
| 12 December 2025
Rivaroxaban is an oral direct factor Xa inhibitor indicated for the prevention of thromboembolic events in patients with atrial fibrillation. Beyond cardiovascular benefits, anticoagulant selection also plays a key role in systemic outcomes, including renal function. Progressive decline in kidney function in patients with atrial fibrillation contributes to increased morbidity and mortality. Therefore, anticoagulant therapy should balance stroke prevention with renal safety.